首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1847094

2025年全球融合蛋白市场

Fusion Proteins: Global Market

出版日期: 2025年10月15日 | 出版商:

BCC Research | 英文 127 Pages | 订单完成后即时交付

价格

简介目录图表

全球融合蛋白市场预计将从 2025 年的 363 亿美元成长到 2030 年底的 649 亿美元，2025 年至 2030 年的复合年增长率为 12.3%。

预计北美市场将从 2025 年的 133 亿美元成长到 2030 年底的 229 亿美元，2025 年至 2030 年的复合年增长率为 11.6%。预计亚太市场将从 2025 年的 90 亿美元成长到 2030 年底的 176 亿美元，2025 年至 2030 年的复合年增长率为 14.5%。

本报告研究了全球融合蛋白市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测以及各个细分市场和地区的详细分析。

按细分
按配体类型进行的市场分析
关键要点
细胞激素陷阱
肽基融合蛋白
基于受体的融合蛋白
其他的
按行政途径分類的市场分析
关键要点
皮下
玻璃体内
静脉
其他的
市场分析：按应用
关键要点
眼科疾病
自体免疫疾病
代谢紊乱
血液疾病
其他的
地理分布
各地区市场分析
关键要点
北美洲
欧洲
亚太地区
世界其他地区

第六章竞争讯息

关键要点
产业结构
企业市场占有率分析
战略分析

第七章融合蛋白市场的永续性：ESG视角

ESG：简介
ESG风险评估
结论

第八章附录

调查方法
来源
首字母缩写词
公司简介
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
EVIVE BIOTECH
F. HOFFMANN-LA ROCHE LTD.
KINIKSA PHARMACEUTICALS
LILLY USA LLC.
MERCK & CO. INC.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
REMEGEN
SAMSUNG BIOEPIS
SANDOZ GROUP AG
SANOFI
Start-Ups新创企业/市场颠覆者

简介目录图表

Product Code: BIO274A

The global market for fusion proteins is expected to grow from $36.3 billion in 2025 to reach $64.9 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2030.

The North American market for fusion proteins is expected to grow from $13.3 billion in 2025 to reach $22.9 billion by the end of 2030, at a CAGR of 11.6% from 2025 to 2030.

The Asia-Pacific market for fusion proteins is expected to grow from $9 billion in 2025 to reach $17.6 billion by the end of 2030, at a CAGR of 14.5% from 2025 to 2030.

Report Scope

The report provides an overview of the global fusion proteins market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented based on type, route of administration, application and region.

According to type, the market is segmented into cytokine traps, peptide-based fusion proteins, receptor-based fusion proteins and others. Based on application, the market is segmented into ophthalmic conditions, autoimmune diseases, metabolic disorders and hematological diseases. Regarding the route of administration, the market is segmented into intravenous, subcutaneous, intravitreal and others. The report also focuses on regional segmentation, including North America, Europe, Asia-Pacific and the Rest of the World, focusing on major countries in these regions.

The report focuses on the major driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance developments and discusses pipeline activities and emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section featuring company profiles with detailed information about leading companies. The scope of the report focuses on Fc-fusion protein products.

Report Includes

92 data tables and 51 additional tables
An overview of the global market for fusion proteins (genetically engineered recombinant therapeutics)
Analyses of the global market trends, with historical market revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
Estimates of the market size and revenue growth prospects, along with a corresponding market share analysis by ligand type, route of administration, application, and region
Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
Impact analysis of U.S. tariff laws, as well as use cases of AI adoption on the fusion proteins market
Insights derived from Porter's Five Forces model, as well as global supply chain analyses
Information on emerging trends and applications in diagnostics and research industries, ongoing research activities, newly approved products, and underlying clinical trials
Identification of the major companies involved in the production and modification of fusion proteins, and analysis of the competitive landscape of the market
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
A relevant patent analysis, featuring key granted and published patents
Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
Profiles of the leading companies, including Regeneron Pharmaceuticals Inc., Bristol Myers Squibb Co., Lilly, Amgen Inc., and Sanofi

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

Chapter 2 Market Overview

Overview
Technology Background
The Advantages of Fc-Fusion Proteins
Porter's Five Forces Analysis in the Fusion Proteins Market
Macroeconomic Factors Analysis
Impact of U.S. Tariffs
Government Policies on Drug Prices
Geopolitical Factors

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Need to Improve Pharmacokinetic and Pharmacodynamic Properties of Existing Protein Drugs
Demand for Targeted Therapeutics
Market Restraints
Manufacturing Challenges
Side Effects and Immunogenicity Risks
Market Opportunities
Diagnostic Applications of Fusion Proteins
Label Expansions and Drugs with Extended Duration

Chapter 4 Emerging Technologies and Pipeline Analysis

Key Takeaways
Emerging Technologies
Antibody-Directed Enzyme Prodrug Therapy
Artificial Intelligence for Fusion Protein Engineering
Bifunctional Fusion Proteins for Cancer Therapy
Pipeline Analysis

Chapter 5 Market Segmentation Analysis

Segmental Breakdown
Market Analysis by Ligand Type
Key Takeaways
Cytokine Traps
Peptide-Based Fusion Proteins
Receptor-Based Fusion Proteins
Others
Market Analysis by Route of Administration
Key Takeaways
Subcutaneous
Intravitreal
Intravenous
Others
Market Analysis by Application
Key Takeaways
Ophthalmic Conditions
Autoimmune Diseases
Metabolic Disorders
Hematological Diseases
Others
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Competitive Intelligence

Key Takeaways
Industry Structure
Company Share Analysis of the Fusion Proteins Market
Strategic Analysis

Chapter 7 Sustainability in the Fusion Proteins Market: An ESG Perspective

Introduction to ESG
ESG Risk Ratings
Conclusion

Chapter 8 Appendix

Methodology
Sources
Acronyms
Company Profiles
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
EVIVE BIOTECH
F. HOFFMANN-LA ROCHE LTD.
KINIKSA PHARMACEUTICALS
LILLY USA LLC.
MERCK & CO. INC.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
REMEGEN
SAMSUNG BIOEPIS
SANDOZ GROUP AG
SANOFI
Emerging Start-ups/Market Disruptors

简介目录图表

List of Tables

Summary Table : Global Fusion Proteins Market, by Region, Through 2030
Table 1 : Active Clinical Trials in the Fusion Proteins Industry, 2025
Table 2 : Global Fusion Proteins Market, by Ligand Type, Through 2030
Table 3 : Global Cytokine Trap Fusion Proteins Market, by Region, Through 2030
Table 4 : Global Peptide-Based Fusion Proteins Market, by Region, Through 2030
Table 5 : Global Receptor-Based Fusion Proteins Market, by Region, Through 2030
Table 6 : Global Other Ligand Type Fusion Proteins Market, by Region, Through 2030
Table 7 : Global Fusion Proteins Market, by ROA, Through 2030
Table 8 : Global Fusion Proteins Market for Subcutaneous ROA, by Region, Through 2030
Table 9 : Global Fusion Proteins Market for Intravitreal ROA, by Region, Through 2030
Table 10 : Global Fusion Proteins Market for Intravenous ROA, by Region, Through 2030
Table 11 : Global Fusion Proteins Market for Other ROA, by Region, Through 2030
Table 12 : Global Fusion Proteins Market, by Application, Through 2030
Table 13 : Global Fusion Proteins Market for Ophthalmic Conditions, by Region, Through 2030
Table 14 : Global Fusion Proteins Market for Autoimmune Diseases, by Region,Through 2030
Table 15 : Global Fusion Proteins Market for Metabolic Disorders, by Region, Through 2030
Table 16 : Global Fusion Proteins Market for Hematological Diseases, by Region, Through 2030
Table 17 : Global Fusion Proteins Market for Other Applications, by Region, Through 2030
Table 18 : Global Fusion Proteins Market, by Region, Through 2030
Table 19 : North American Fusion Proteins Market, by Country, Through 2030
Table 20 : North American Fusion Proteins Market, by Ligand Type, Through 2030
Table 21 : North American Fusion Proteins Market, by ROA, Through 2030
Table 22 : North American Fusion Proteins Market, by Application, Through 2030
Table 23 : U.S. Fusion Proteins Market, by Ligand Type, Through 2030
Table 24 : U.S. Fusion Proteins Market, by ROA, Through 2030
Table 25 : U.S. Fusion Proteins Market, by Application, Through 2030
Table 26 : Canadian Fusion Proteins Market, by Ligand Type, Through 2030
Table 27 : Canadian Fusion Proteins Market, by ROA, Through 2030
Table 28 : Canadian Fusion Proteins Market, by Application, Through 2030
Table 29 : Mexican Fusion Proteins Market, by Ligand Type, Through 2030
Table 30 : Mexican Fusion Proteins Market, by ROA, Through 2030
Table 31 : Mexican Fusion Proteins Market, by Application, Through 2030
Table 32 : European Fusion Proteins Market, by Country, Through 2030
Table 33 : European Fusion Proteins Market, by Ligand Type, Through 2030
Table 34 : European Fusion Proteins Market, by ROA, Through 2030
Table 35 : European Fusion Proteins Market, by Application, Through 2030
Table 36 : German Fusion Proteins Market, by Ligand Type, Through 2030
Table 37 : German Fusion Proteins Market, by ROA, Through 2030
Table 38 : German Fusion Proteins Market, by Application, Through 2030
Table 39 : U.K. Fusion Proteins Market, by Ligand Type, Through 2030
Table 40 : U.K. Fusion Proteins Market, by ROA, Through 2030
Table 41 : U.K. Fusion Proteins Market, by Application, Through 2030
Table 42 : French Fusion Proteins Market, by Ligand Type, Through 2030
Table 43 : French Fusion Proteins Market, by ROA, Through 2030
Table 44 : French Fusion Proteins Market, by Application, Through 2030
Table 45 : Italian Fusion Proteins Market, by Ligand Type, Through 2030
Table 46 : Italian Fusion Proteins Market, by ROA, Through 2030
Table 47 : Italian Fusion Proteins Market, by Application, Through 2030
Table 48 : Spanish Fusion Proteins Market, by Ligand Type, Through 2030
Table 49 : Spanish Fusion Proteins Market, by ROA, Through 2030
Table 50 : Spanish Fusion Proteins Market, by Application, Through 2030
Table 51 : Rest of Europe Fusion Proteins Market, by Ligand Type, Through 2030
Table 52 : Rest of Europe Fusion Proteins Market, by ROA, Through 2030
Table 53 : Rest of Europe Fusion Proteins Market, by Application, Through 2030
Table 54 : Asia-Pacific Fusion Proteins Market, by Country, Through 2030
Table 55 : Asia-Pacific Fusion Proteins Market, by Ligand Type, Through 2030
Table 56 : Asia-Pacific Fusion Proteins Market, by ROA, Through 2030
Table 57 : Asia-Pacific Fusion Proteins Market, by Application, Through 2030
Table 58 : Chinese Fusion Proteins Market, by Ligand Type, Through 2030
Table 59 : Chinese Fusion Proteins Market, by ROA, Through 2030
Table 60 : Chinese Fusion Proteins Market, by Application, Through 2030
Table 61 : Japanese Fusion Proteins Market, by Ligand Type, Through 2030
Table 62 : Japanese Fusion Proteins Market, by ROA, Through 2030
Table 63 : Japanese Fusion Proteins Market, by Application, Through 2030
Table 64 : South Korean Fusion Proteins Market, by Ligand Type, Through 2030
Table 65 : South Korean Fusion Proteins Market, by ROA, Through 2030
Table 66 : South Korean Fusion Proteins Market, by Application, Through 2030
Table 67 : Indian Fusion Proteins Market, by Ligand Type, Through 2030
Table 68 : Indian Fusion Proteins Market, by ROA, Through 2030
Table 69 : Indian Fusion Proteins Market, by Application, Through 2030
Table 70 : Australian Fusion Proteins Market, by Ligand Type, Through 2030
Table 71 : Australian Fusion Proteins Market, by ROA, Through 2030
Table 72 : Australian Fusion Proteins Market, by Application, Through 2030
Table 73 : Rest of Asia-Pacific Fusion Proteins Market, by Ligand Type, Through 2030
Table 74 : Rest of Asia-Pacific Fusion Proteins Market, by ROA, Through 2030
Table 75 : Rest of Asia-Pacific Fusion Proteins Market, by Application, Through 2030
Table 76 : RoW Fusion Proteins Market, by Subregion, Through 2030
Table 77 : RoW Fusion Proteins Market, by Ligand Type, Through 2030
Table 78 : RoW Fusion Proteins Market, by ROA, Through 2030
Table 79 : RoW Fusion Proteins Market, by Application, Through 2030
Table 80 : Recent Developments in the Fusion Proteins Market, 2022-2025
Table 81 : ESG Risk Rankings for Fusion Protein Drugs Companies, 2025
Table 82 : Report Information Sources
Table 83 : Abbreviations Used in the Global Fusion Proteins Market
Table 84 : Amgen Inc.: Company Snapshot
Table 85 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 86 : Amgen Inc.: Product Portfolio
Table 87 : Amgen Inc.: News/Key Developments, 2022-2025
Table 88 : AstraZeneca: Company Snapshot
Table 89 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 90 : AstraZeneca: Product Portfolio
Table 91 : AstraZeneca: News/Recent Developments, 2023
Table 92 : Bayer AG: Company Snapshot
Table 93 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 94 : Bayer AG: Product Portfolio
Table 95 : Bayer AG: News/Recent Developments, 2025
Table 96 : Bristol-Myers Squibb Co.: Company Snapshot
Table 97 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 98 : Bristol-Myers Squibb Co.: Product Portfolio
Table 99 : Bristol-Myers Squibb Co.: News/Key Developments, 2025
Table 100 : Evive Biotech: Company Snapshot
Table 101 : Evive Biotech: Product Portfolio
Table 102 : Evive Biotech: News/Key Developments, 2024-2025
Table 103 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 104 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 105 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 106 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 107 : Kiniksa Pharmaceuticals: Company Snapshot
Table 108 : Kiniksa Pharmaceuticals: Financial Performance, FY 2023 and 2024
Table 109 : Kiniksa Pharmaceuticals: Product Portfolio
Table 110 : Kiniksa Pharmaceuticals: News/Key Developments, 2022
Table 111 : Lilly USA LLC.: Company Snapshot
Table 112 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 113 : Lilly USA LLC.: Product Portfolio
Table 114 : Lilly USA LLC.: News/Key Developments, 2025
Table 115 : Merck & Co. Inc.: Company Snapshot
Table 116 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 117 : Merck & Co. Inc.: Product Portfolio
Table 118 : Merck & Co. Inc.: News/Key Developments, 2023
Table 119 : Pfizer Inc.: Company Snapshot
Table 120 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 121 : Pfizer Inc.: Product Portfolio
Table 122 : Pfizer Inc.: News/Key Developments, 2022
Table 123 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 124 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 125 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 126 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2023
Table 127 : RemeGen: Company Snapshot
Table 128 : RemeGen: Financial Performance, FY 2023 and 2024
Table 129 : RemeGen: Product Portfolio
Table 130 : RemeGen: News/Key Developments, 2025
Table 131 : Samsung Bioepis: Company Snapshot
Table 132 : Samsung Bioepis: Product Portfolio
Table 133 : Samsung Bioepis: News/Key Developments, 2025
Table 134 : Sandoz Group AG: Company Snapshot
Table 135 : Sandoz Group AG: Financial Performance, FY 2023 and 2024
Table 136 : Sandoz Group AG: Product Portfolio
Table 137 : Sandoz Group AG: News/Key Developments, 2025
Table 138 : Sanofi: Company Snapshot
Table 139 : Sanofi: Financial Performance, FY 2023 and 2024
Table 140 : Sanofi: Product Portfolio
Table 141 : Sanofi: News/Key Developments, 2024
Table 142 : List of a Few Emerging Startups

List of Figures

Summary Figure : Global Market Shares of Fusion Proteins, by Region, 2024
Figure 1 : Characteristics of Therapeutic Fusion Proteins
Figure 2 : Porter's Five Forces Analysis: Fusion Proteins Market
Figure 3 : Global Market Dynamics of Fusion Proteins
Figure 4 : Emerging Technologies in the Fusion Proteins Market
Figure 5 : Global Market Shares of Fusion Proteins, by Ligand Type, 2024
Figure 6 : Global Market Shares of Fusion Proteins, by ROA, 2024
Figure 7 : Global Market Shares of Fusion Proteins, by Application, 2024
Figure 8 : Global Market Shares of Fusion Proteins, by Region, 2024
Figure 9 : North American Market Shares of Fusion Proteins, by Country, 2024
Figure 10 : European Market Shares of Fusion Proteins, by Country, 2024
Figure 11 : Asia-Pacific Market Shares of Fusion Proteins, by Country, 2024
Figure 12 : RoW Market Shares of Fusion Proteins, by Subregion, 2024
Figure 13 : Global Fusion Proteins Market Share Analysis, by Company, 2024
Figure 14 : Key ESG Metrics of Fusion Proteins Companies
Figure 15 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 16 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 17 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
Figure 18 : AstraZeneca: Revenue Share, by Country/Region, FY 2024
Figure 19 : Bayer AG: Revenue Share, by Business Unit, FY 2024
Figure 20 : Bayer AG: Revenue Share, by Country/Region, FY 2024
Figure 21 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 22 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 23 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 24 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 25 : Kiniksa Pharmaceuticals: Revenue Share, by Business Unit, FY 2024
Figure 26 : Lilly USA LLC.: Revenue Share, by Business Unit, FY 2024
Figure 27 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
Figure 28 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
Figure 29 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
Figure 30 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 31 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 32 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
Figure 33 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024
Figure 34 : RemeGen: Revenue Share, by Country/Region, FY 2024
Figure 35 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2024
Figure 36 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2024
Figure 37 : Sanofi: Revenue Share, by Country/Region, FY 2024

02-2729-4219

+886-2-2729-4219

License/价格

2025年全球融合蛋白市场

Fusion Proteins: Global Market